Form 8-K - Current report:
SEC Accession No. 0001628280-22-004562
Filing Date
2022-03-01
Accepted
2022-03-01 17:04:57
Documents
13
Period of Report
2022-03-01
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K espr-20220301.htm   iXBRL 8-K 41039
2 EX-10.1 a101employmentagreementdat.htm EX-10.1 75400
  Complete submission text file 0001628280-22-004562.txt   274316

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT espr-20220301.xsd EX-101.SCH 1921
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT espr-20220301_lab.xml EX-101.LAB 24945
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT espr-20220301_pre.xml EX-101.PRE 13154
7 EXTRACTED XBRL INSTANCE DOCUMENT espr-20220301_htm.xml XML 11019
Mailing Address 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR MI 48108
Business Address 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR MI 48108 734-887-3903
Esperion Therapeutics, Inc. (Filer) CIK: 0001434868 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35986 | Film No.: 22699455
SIC: 2834 Pharmaceutical Preparations